Genmab Says Ovarian Cancer Drug Met Two Phase 3 Endpoints

Genmab said its ovarian cancer treatment met the primary endpoint and a key secondary endpoint in a Phase 3 trial. The company said Friday that Rina-S, also known as rinatabart sesutecan, significantly reduced the risk of disease progression among patients with platinum-resistant ovarian cancer. The supplied section ends mid-sentence, so no further details are available.